Research advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma
10.3760/cma.j.cn115610-20210122-00037
- VernacularTitle:胆管癌免疫检查点抑制剂治疗研究进展
- Author:
Jiang CHANG
;
Yichao GU
;
Xiangcheng LI
- From:
Chinese Journal of Digestive Surgery
2021;20(2):250-254
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma is a rarely malignant tumor with poor overall prognosis. Radical surgery is the only strategy to improve the long-term survival of patients with cholangio-carcinoma of early-stage. For most patients with advanced cholangiocarcinoma, systematic treatment has become the main strategy. But the available first-line drugs for the treatment of cholangiocarcinoma are limited and the curative effect is limited. In recent years, immunotherapy strategies such as immune checkpoint inhibitors have achieved encouraging results in a variety of solid tumors by using the host immune system to carry out effective anti-tumor responses. The authors summarize the research advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma.
